Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02424396 (ClinicalTrials.gov)	June 13, 2016	20/4/2015	Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis	Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study	Relapsing Remitting Multiple Sclerosis	Drug: IL2;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Fondation ARSEP/AFM	Completed	18 Years	65 Years	All	30	Phase 2	France
2	NCT02769767 (ClinicalTrials.gov)	August 2012	25/4/2016	Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.	Association of Polymorphisms of the Interleukin-7 Receptor-a (IL-7R), Glypican 5 (GPC5), Interleukin-2 Receptor-a (IL2-RA) , Human Leukocyte Antigen Class II Beta Chain (HLA-DRB1) Genes and Treatment Response in Multiple Sclerosis (MS).	Multiple Sclerosis, Relapsing-Remitting	Genetic: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.	Instituto Jalisciense de Cancerologia	Instituto Mexicano del Seguro Social;University of Guadalajara	Recruiting	18 Years	65 Years	Both	500	N/A	Mexico